{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:41Z","timestamp":1790874941886,"version":"4.1.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cannabis &amp; Cannabinoid Research"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Tourette's syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics and other comorbidities. Clinical recommendations for the use of medical cannabis are established, yet further guidance is needed. The aim of this study was to describe the experience of patients with TS with medical cannabis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>TS patients were recruited from a registry of patients (\u201cTikun Olam\u201d company). Questionnaires were answered before and after 6 months of treatment. Patients were divided into two groups: (A) patients who responded and (B) patients who did not respond to the follow-up questionnaire. In group A, an analysis was made to evaluate the presence and frequency of motor and vocal tics. The patients' general mood, employment status, quality of life, and comorbidities were also included in the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy patients were identified. The tetrahydrocannabinol and cannabidiol mean daily dose was 123 and 50.5\u2009mg, respectively. In group A, a statistically significant improvement was identified in quality of life (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.005), employment status (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =0.027), and in the reduction of the number of medications (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.005). Sixty-seven percent and 89% of patients with obsessive-compulsive disorder and anxiety comorbidities, respectively, reported an improvement. No statistically significant improvement was identified in motor tics (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =0.375), vocal tics (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &gt;0.999), tics frequency (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =0.062), or general mood (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =0.129). The most frequent adverse effects were dizziness (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =4) and increased appetite (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =3).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Subjective reports from TS patients suggest that medical cannabis may improve their quality of life and comorbidities. More studies are needed to evaluate the efficacy and safety of medical cannabis.<\/jats:p>\n                    <jats:p>\n                      Registry in the MOH:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.moh.gov.sg\/\">https:\/\/www.moh.gov.sg\/<\/jats:ext-link>\n                      (Trial number: 0185-19-ASF)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/can.2022.0112","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T13:30:44Z","timestamp":1667827844000},"page":"293-299","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of Medical Cannabis in Patients with Gilles de la Tourette's Syndrome in a Real-World Setting"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-8642","authenticated-orcid":false,"given":"Dana","family":"Barchel","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel; affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Stolar","sequence":"additional","affiliation":[{"name":"Autistic Spectrum Disorder Clinic, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel; affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Ziv-Baran","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health, Tel-Aviv University, Tel-Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Gueta","sequence":"additional","affiliation":[{"name":"Internal Medicine A, Sheba Medical Center, The Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel-Aviv University, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matitiahu","family":"Berkovitch","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel; affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elkana","family":"Kohn","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel; affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Bar-Lev Schleider","sequence":"additional","affiliation":[{"name":"Research Department, Tikun Olam\u2014Cannbit Pharmaceuticals, Beer-Sheva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14165"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th ed. (DSM-5). American Psychiatric Publishing: Washington DC USA; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2018.09.005"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23434"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13155"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2014.11.005"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00088.x"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1998.tb10127.x"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.9.1359"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.273.5279.1225"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.01.005"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0671-6"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0486-0"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007466"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-021-01832-4"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198812000-00021"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.3.495"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-25028"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0417"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000496355"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.10.004"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2018.0050"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10386"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1377"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d236ec"},{"issue":"2","key":"e_1_3_4_27_2","first-page":"39","article-title":"Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome: Case report","volume":"2","author":"Szejko N","year":"2018","unstructured":"Szejko N, , Jakubovski E, , Fremer C, et al. Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome: Case report. Eur J Med Case Rep, 2018; 2(2):39\u201341; doi: 10.24911\/ejmcr\/2\/11","journal-title":"Eur J Med Case Rep"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(02)00580-9"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2003.76"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327890.02893.61"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073812457462"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/732038"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867415594429"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2013.08.012"}],"container-title":["Cannabis &amp; Cannabinoid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/can.2022.0112","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2022.0112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2022.0112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:56Z","timestamp":1777385516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/can.2022.0112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["10.1089\/can.2022.0112"],"URL":"https:\/\/doi.org\/10.1089\/can.2022.0112","relation":{},"ISSN":["2578-5125","2378-8763"],"issn-type":[{"value":"2578-5125","type":"print"},{"value":"2378-8763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}